Antifibrinolytics and cardiac surgery: The past, the present, and the future

Area of Science:

• Cardiology
• Pharmacology
• Anesthesiology

Background:

• Cardiac surgery frequently leads to substantial blood loss, often requiring transfusions.
• Minimizing transfusion risks involves pharmacological and non-pharmacological strategies.
• Antifibrinolytic drugs are the primary pharmacological approach to reduce surgical bleeding.

Purpose of the Study:

• To review current pharmacological strategies for managing blood loss in cardiac surgery.
• To discuss the evolution and current status of antifibrinolytic drugs.
• To explore emerging agents and their potential advantages.

Main Methods:

• Review of existing literature on antifibrinolytic agents in cardiac surgery.
• Analysis of the efficacy and safety profiles of different drug classes.
• Discussion of clinical considerations, including side effects and dosing.

Main Results:

• Aprotinin, initially widely used, faced challenges but is re-emerging.
• Lysine analogs (e.g., tranexamic acid, aminocaproic acid) are now commonly used.
• Newer agents like nonsaccharide glycosaminoglycans are being investigated for improved outcomes.

Conclusions:

• Antifibrinolytic drugs are essential for managing blood loss in cardiac surgery.
• Careful consideration of drug-specific side effects and dosing is necessary.
• Novel antifibrinolytics hold promise for overcoming limitations of current therapies.